Saw palmetto extract (SPE) has been widely used for the treatment of lower urinary-tract symptoms secondary to benign prostatic hyperplasia. The mechanisms of pharmacological effects of SPE include the inhibition of 5a-reductase, antiandrogenic effects, anti-proliferative effects, and anti-inflammatory effects. Previously, we showed that SPE bound actively to a1-adrenergic, muscarinic and 1,4-dihydropyridine calcium channel (1,4-DHP) receptors in the prostate and bladder of rats, whereas its active constituents have not been fully clarified. The present investigation is aimed to identify the main active components contained in hexane and diethyl ether extracts of SPE with the use of column chromatography and preparative HPLC. Based on the binding activity with a1-adrenergic, muscarinic, and 1,4-DHP receptors, both isolated oleic and lauric acids were deduced to be active components. Authentic samples of oleic and lauric acids also exhibited similar binding activities to these receptors as the fatty acids isolated from SPE, consistent with our findings. In addition, oleic and lauric acids inhibited 5a-reductase, possibly leading to therapeutic effects against benign prostatic hyperplasia and related lower urinary-tract symptoms.
Introduction
Benign prostatic hyperplasia (BPH) and related lower urinarytract symptoms (LUTS) are common disorders in aging men. A clinical manifestation of BPH is a progressive enlargement of the prostate, resulting in compression of the urethra, and the initiation of both obstructive and irritative symptoms. 1 For a clinical treatment of BPH and LUTS, 5a-reductase inhibitors and a1-adrenoceptor antagonists have been used. 2 The inhibition of 5a-reductase causes a significant decrease in dihydrotestosterone (DHT), resulting in a reduction of the prostate, and an inhibition of a1-adrenergic receptors relaxes the prostatic smooth muscle and decreases urethral resistance.
Because of its improvement of the urinary-tract symptoms and flow measures in men with BPH, 3 plant extracts, especially saw palmetto extract (SPE), have been widely used in the treatment of BPH and related LUTS in many European countries, in which phytotherapeutic preparations represent approximately l/3 of total sales of all therapeutic agents for the treatment of BPH. SPE is constituted of both saturated and unsaturated fatty acids by more than 90%, which are present in mixture of free and esterified forms. 4 SPE has an ability to inhibit type 1 and 2 isozymes of 5a-reductase, 5, 6 and other biological functions of SPE were found to stimulate the a1-adrenoceptor, 7 and produce anti-androgenic, 8 anti-proliferative, 9 and anti-inflammatory effects. 10 Recently, our group demonstrated that SPE could inhibit specific bindings of radioligands for muscarinic and 1,4-dihydropyridine calcium channel (1,4-DHP) receptors. [11] [12] [13] Despite the multiple function of SPE, the pharmacologically active constituents in SPE had not been fully clarified.
The main purpose of the present investigation was to isolate bioactive compounds contained in SPE, and to characterize their pharmacological properties. SPE was fractionated on column chromatography and preparative HPLC, and the biological activities of each fraction were assessed, while focusing on the binding activity to a1-adrenergic, muscarinic, and 1,4-DHP receptors. Upon guidance on these pharmacological effects, some fatty acids in SPE were identified as being bioactive components, and they also exhibited potent inhibition of 5a-reductase, possibly leading to therapeutic effects against BPH and LUTS.
Experimental
Chemicals SABAL SELECT, a saw palmetto extract prepared with supercritical CO2, 4 was provided by Indena Japan (Tokyo, Japan Extraction and isolation SPE (2 mL) was diluted with 50 mL of methanol and 100 mL of distilled water. The diluted SPE was extracted with 100 mL of hexane three times. The aqueous residue was extracted with 100 mL of diethyl ether (Et2O) twice. The hexane and Et2O layers were evaporated in vacuo to dryness. The Et2O extract was applied to a silica-gel column (f20 ¥ 100 mm, 10 g, particle size 0.040 -0.063 mm, Merck, Darmstadt, Germany), developed with a solvent gradient of hexane-Et2O mixtures of increasing polarity. Further fractionation of the active fraction (18 mg), the eluate with hexane/Et2O (4:1), was performed on an Xterra MS C8 column (f4.6 ¥ 100 mm, 3.5 mm, Waters, Milford, MA) using an Agilent 1100 HPLC system (Agilent Technologies, Palo Alto, CA) with an Agilent 1100 autosampler, an Agilent 1100 binary pump and an Agilent 1100 photodiode-array detector. The samples were separated using a gradient mobile phase consisting of distilled water (A) and acetonitrile (B) with a detection wavelength of 220 nm. The gradient conditions of the mobile phase were 0 -15 min, 70 -95% B; 15 -20 min, 95% B, and the flow rate was set at 0.5 mL/min. The temperature of a column oven was set at 30˚C. Each eluate from the column during 1 min was collected, dried and reconstituted in ethanol.
To isolate oleic and lauric acids, a preparative HPLC was carried out on YMC-Pack ODS column (f20 ¥ 250 mm, 5 mm, YMC, Kyoto, Japan), and the mobile phase consisted of distilled water/acetonitrile (5:95) with a flow rate of 15 mL/min at ambient temperature. Dried Et2O extract (2.4 g) was dissolved in 6 mL of ethanol and subjected to 30-times repeated separations, resulting in the isolation of purified oleic acid (0.34 g) and lauric acid (0.40 g).
Structural elucidation on isolated and authentic samples
Structures of isolated chemicals were assessed by LC/ESI-MS and NMR spectral analyses. LC/ESI-MS data were recorded on a Micromass LCT (Manchester, UK) and a Waters 2790 Alliance HPLC system. The 1D-and 2D-1 H NMR (500 MHz) and 13 C NMR (125 MHz) data were recorded in CDCl3 on a Bruker Avance 500 NMR spectrometer (Rheinstetten, Germany), and each signal in 1 H-and 13 C-NMR spectral data was assigned as follows. 
Oleic acid (isolated).

Radioreceptor binding assay
Radioligand binding assays for muscarinic, a1-adrenergic, [14] [15] [16] Rats were killed by taking blood from the descending aorta under temporary anesthesia with ether, and the brain (except for cerebellum) was excised after being perfused with cold saline from the aorta. Rat brain was homogenized by a Kinematica Polytron homogenizer in 19 volumes of ice-cold 50 mM TrisHCl buffer (pH 7.4). The homogenate was then centrifuged at 40000 ¥ g for 20 min at 4˚C, and a suspension of the pellet was centrifuged again under the same condition. The resulting pellet was finally suspended in 29 volumes of 50 mM Tris-HCl buffer (pH 7.4). In the presence of various concentrations of fatty acids, the brain homogenate (3 mg) was incubated with 250 pM [ 3 H]NMS in a total volume of 0.5 mL in a 50 mM HEPES buffer (pH 7.4). Incubation was carried out for 60 min at 25˚C. In the presence of various concentrations of fatty acids, the brain homogenate (10 mg) was incubated with 250 pM [ Incubation was carried out in the dark with a sodium lamp for 60 min at 25˚C. Each reaction was terminated by rapid filtration (Cell Harvester, Brandel Co., Gaithersburg, MD) through Whatman GF/B glass fiber filters, and the filters were then rinsed twice with 3 mL of ice-cold 50 mM Na/K + phosphate buffer. Tissue-bound radioactivity was extracted from the filters by immersing them overnight in scintillation fluid, and the radioactivity was determined by a liquid-scintillation counter. Specific binding of 
Measurement of 5a-reductase activity
The 5a-reductase activity was determined by LC/ESI-MS, according to a modified procedure of Mitamura's method. 17 Rat liver microsome was prepared as reported by Liu et al. 18 with some modifications. From a female rat, the liver was removed and minced tissue was homogenized in 4 volumes of medium A (0.32 M sucrose, 1 mM dithiothreitol, and 20 mM sodium phosphate, pH 6.5). The homogenate was then centrifuged at 10000 ¥ g for 10 min. The resulting supernatant from the centrifugations was further centrifuged at 105000 ¥ g for 1 h twice. Washed microsomes were suspended in 1 pellet volume of medium A, and the dispersion of the microsomes was achieved using a syringe with 18, 23, and 26 G needles in succession. The protein concentrations were measured by a method of Bradford. 19 The microsome suspension was stored at -80˚C until use. A complete reaction mixture included 1 mM dithiothreitol, 20 mM phosphate buffer (pH 6.5), 50 mM testosterone, 167 mM NADPH, and the microsomes (0.2 mg of protein) in a final volume of 0.3 mL. Fatty acids were added to the solution at several concentrations, and an enzymatic reaction was initiated by the addition of microsomes and NADPH into the pre-heated reaction solution in a tube. After 10 min of incubation at 37˚C, the incubation was terminated by adding 10 mL of 2 mol/L NaOH. To extract metabolites, 0.6 mL of ethyl acetate and 10 mL of internal standard (30 mM dexamethasone) were added and mixed well. The organic layer was evaporated with a nitrogen gas stream, and the residue was dissolved in 50 mL of methanol.
An Alliance 2795 HPLC system was coupled to a ZQ2000 (Waters), operating in the positive ion mode. ). The source temperature was set at 120˚C with a cone gas flow of 62 L/h, a desolvation gas temperature of 350˚C, and a nebulization gas flow of 323 L/h. The capillary voltage was set at 3.1 kV with a cone voltage of 40 V. A 5-mL aliquot of sample was injected onto an Xterra MS C18 column (2.1 ¥ 150 mm, 5 mm, Waters), maintained at 40˚C. The samples were separated using a gradient mobile phase consisting of 0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B), with the flow rate was set at 0.25 mL/min. The gradient condition of the mobile phase was 0 -5 min, 45 -95% B; 5 -7 min, 95% B.
Results and Discussion
Isolation and structural elucidation of active compounds
To deduce the chemical series of constituents in SPE, a 1 H NMR spectral analysis of SPE was made (Fig. 1) . Aliphatic signals at d 0.8 to 2.4 and olefinic signals at d 5.4 were detected, and these signals suggested that saturated and unsaturated fatty acids would be the major components in SPE. In addition to free fatty acids, esterified fatty acids seemed to be contained in SPE, as evidenced by the following HMBC data: (1) . These findings were consistent with previous observations that hexane extracts and supercritical fluid CO2 extracts of SPE were composed of free fatty acids (ca. 84%), fatty acid esters (ca. 10%) and other chemical series (<2%) such as phytosterol, aliphatic alcohols and polypyrenic compounds. 4, [20] [21] [22] In H NMR spectroscopic analysis. The active fraction in column chromatography was further fractionated by RP-HPLC, and the receptor binding activity of each fraction was assessed, while focusing on a-adrenergic, muscarinic and 1,4-DHP receptors (Fig. 2) . Some fractions collected, especially fraction numbers 6, 7, 9, 10, 12 and 13, showed specific binding with these receptors. According to LC/ESI-MS analysis on these fractions, the major components in each fraction were deduced to be lauric acid (fractions 6 and 7), myristic acid (fractions 8 and 9), linoleic acid (fraction 10), palmitic acid (fraction 11), and oleic acid (fractions 12 and 13). Finally, oleic and lauric acids with purities of 93 and 95% were isolated from Et2O extract of SPE by preparative HPLC, the yields of which were found to be 14.2 and 16.7%, respectively. There appeared to be the same proton and carbon signaling patterns in the 1 H and 13 C NMR spectra of isolated and authentic fatty acids. These findings, taken together with our previous findings, 13 suggested that both oleic and lauric acids could be active components of SPE with specific affinity toward a-adrenergic, muscarinic and 1,4-DHP receptors. Fig. 1 1 H NMR spectrum of SPE in CDCl3 (500 MHz). 
Pharmacological characterization of isolated fatty acids
Two fatty acids were isolated as major components in the active fraction of SPE, and their receptor-binding activities were assessed in more detail (Fig. 3) . Both oleic and lauric acids, isolated from SPE, exhibited significant inhibition on the specific binding of Authentic fatty acids could mimic the receptor-binding activities of the isolated fatty acids, in particular, affinity of isolated and authentic oleic and lauric acids toward a1-adrenergic, 1,4-DHP and the muscarinic receptors were found to be roughly equipotent (Table 1) . These data would verify the essential role of oleic and lauric acids in the SPE-medication. Although SPE contains oleic and lauric acids with similar content (ca. 15%), the IC50 values of oleic acid towards autonomic receptors were lower than that of lauric acid. These data suggested that oleic acid has a greater contribution than lauric acid in the clinical treatment of BPH and LUTS using SPE.
Symptoms of BPH were caused by two obstructive mechanisms: (1) dynamic obstruction due to an excess sympathetic tone in the prostate and bladder neck, and (2) mechanical obstruction of the urethra, from an overgrowth of epithelial tissue in the transitional zone of the prostate. 23 For the relief of dynamic obstruction, a1-adrenergic antagonists, such as terazosin, doxazosin and prazosin, are currently used, because of their potent relaxant activities in the smooth muscle of the prostate. In this context, fatty acids in SPE would also be efficacious in the attenuation of dynamic obstruction, leading to improvements of the BPH symptoms. Mechanical obstruction can be attenuated by 5a-reductase inhibitors, such as finasteride, chlormadinone and allylestrenol, the mechanisms of which are identified as inhibition of the chemical conversion from testosterone into 5a-dihydrotestosterone. In addition to these synthetic pharmaceutical agents, some aliphatic unsaturated fatty acids have been shown to inhibit human or rat microsomal 5a-reductase activity. 24 These findings prompted us to assess the inhibitory effect of fatty acids, isolated from SPE, on 5a-reductase activity using LC/ESI-MS. As shown in Table 1 , both isolated oleic and lauric acids showed potent inhibition of the 5a-reductase activity, giving IC50 values of 54.5 ± 3.0 and 66.2 ± 3.0 mg/mL, respectively. Authentic fatty acids also inhibited the 5a-reductase activity with almost the same IC50 values. Thus, fatty acids in SPE might be effective for improving mechanical obstruction of the urethra. These findings, taken together with the pathogenesis of BPH, proposed the high therapeutic potential of SPE against BPH and LUTS, possibly via the attenuation of both dynamic and mechanical obstruction in the urinary tissues.
Conclusion
Upon column and preparative-HPLC separations, oleic and lauric acids could be identified as pharmacological active components of SPE, and they exhibited specific binding with autonomic receptors, including a1-adrenergic, muscarinic and 1,4-DHP receptors. LC/ESI-MS-based enzyme experiments revealed the potent inhibitory effects of oleic and lauric acids on 5a-reductase activity. Authentic samples also showed similar biological activities and spectroscopic data in MS and NMR spectral analyses, supporting the identification of isolated chemicals. In conclusion, free fatty acids, especially oleic and lauric acids, were found to be responsible for the pharmacological effects of SPE, and additional characterization of active components in SPE might provide further insight into clinical treatments of BPH and LUTS.
